These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

311 related items for PubMed ID: 20962062

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
    Hsiao P, Bui T, Ho RJ, Unadkat JD.
    Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
    [Abstract] [Full Text] [Related]

  • 3. A simplified protocol employing elacridar in rodents: a screening model in drug discovery to assess P-gp mediated efflux at the blood brain barrier.
    Kallem R, Kulkarni CP, Patel D, Thakur M, Sinz M, Singh SP, Mahammad SS, Mandlekar S.
    Drug Metab Lett; 2012 Jun 01; 6(2):134-44. PubMed ID: 23061481
    [Abstract] [Full Text] [Related]

  • 4. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
    Hsiao P, Sasongko L, Link JM, Mankoff DA, Muzi M, Collier AC, Unadkat JD.
    J Pharmacol Exp Ther; 2006 May 01; 317(2):704-10. PubMed ID: 16415090
    [Abstract] [Full Text] [Related]

  • 5. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans.
    Sugimoto H, Hirabayashi H, Amano N, Moriwaki T.
    Drug Metab Dispos; 2013 Apr 01; 41(4):683-8. PubMed ID: 23340958
    [Abstract] [Full Text] [Related]

  • 6. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
    Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, Surry DD.
    Drug Metab Dispos; 2011 Feb 01; 39(2):275-82. PubMed ID: 21075975
    [Abstract] [Full Text] [Related]

  • 7. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies.
    Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF.
    J Pharmacol Exp Ther; 2001 Feb 01; 296(2):551-7. PubMed ID: 11160643
    [Abstract] [Full Text] [Related]

  • 8. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y, Ohtsuki S, Kamiie J, Terasaki T.
    J Pharmacol Exp Ther; 2011 Nov 01; 339(2):579-88. PubMed ID: 21828264
    [Abstract] [Full Text] [Related]

  • 9. Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.
    Uchida Y, Wakayama K, Ohtsuki S, Chiba M, Ohe T, Ishii Y, Terasaki T.
    J Pharmacol Exp Ther; 2014 Sep 01; 350(3):578-88. PubMed ID: 24947467
    [Abstract] [Full Text] [Related]

  • 10. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio.
    Ohe T, Sato M, Tanaka S, Fujino N, Hata M, Shibata Y, Kanatani A, Fukami T, Yamazaki M, Chiba M, Ishii Y.
    Drug Metab Dispos; 2003 Oct 01; 31(10):1251-4. PubMed ID: 12975334
    [Abstract] [Full Text] [Related]

  • 11. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
    Zong J, Pollack GM.
    J Pharmacol Exp Ther; 2003 Aug 01; 306(2):556-62. PubMed ID: 12721332
    [Abstract] [Full Text] [Related]

  • 12. P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies.
    Wandel C, Kim RB, Kajiji S, Guengerich P, Wilkinson GR, Wood AJ.
    Cancer Res; 1999 Aug 15; 59(16):3944-8. PubMed ID: 10463589
    [Abstract] [Full Text] [Related]

  • 13. Comparison of drug efflux transport kinetics in various blood-brain barrier models.
    Bachmeier CJ, Trickler WJ, Miller DW.
    Drug Metab Dispos; 2006 Jun 15; 34(6):998-1003. PubMed ID: 16554372
    [Abstract] [Full Text] [Related]

  • 14. Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro.
    Wandel C, Kim RB, Guengerich FP, Wood AJ.
    Drug Metab Dispos; 2000 Aug 15; 28(8):895-8. PubMed ID: 10901697
    [Abstract] [Full Text] [Related]

  • 15. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
    Gnoth MJ, Sandmann S, Engel K, Radtke M.
    Drug Metab Dispos; 2010 Aug 15; 38(8):1341-6. PubMed ID: 20413726
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity.
    Madlova M, Bosquillon C, Asker D, Dolezal P, Forbes B.
    J Pharm Pharmacol; 2009 Mar 15; 61(3):293-301. PubMed ID: 19222901
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.